SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis

The suppressor of zeste-12 protein (SUZ12), a core component of Polycomb repressive complex 2 (PRC2), is implicated in transcriptional silencing by generating di- and tri-methylation of lysine 27 on histone H3 (H3K27Me3). Although SUZ12 is known to be of great importance in several human cancer tumorigenesis, limited data are available on the expression profile and functional role of SUZ12 in non-small cell lung cancer (NSCLC). Here, we determined the expression level of SUZ12 in 40 paired clinical NSCLC tissues and adjacent normal tissues by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The results showed that SUZ12 was anomalously expressed in NSCLC tissues compared to adjacent noncancerous tissues (P < 0.05) and was highly correlated to tumor size, lymph node metastasis, and clinical stages (P < 0.05). Additionally, siRNA-mediated knockdown of SUZ12 could inhibit tumor cell growth, migration, and invasion, indicating that SUZ12 might function as an oncogene in NSCLC initiation and progression. Furthermore, we found that SUZ12 silencing significantly reduced the expression levels of transcription factor transcription factor E2F1 (E2F1) as well as potential metastasis promoters Rho-associated, coiled-coil-containing protein kinase 1 (ROCK1) and roundabout homolog 1 (ROBO1) through Western blot analysis. Altogether, we provide evidences suggesting that SUZ12 is an oncogene in NSCLC and can regulate NSCLC cells proliferation and metastasis partly via reducing E2F1, ROCK1, and ROBO1. Thus, SUZ12 may represent a new potential diagnostic marker for NSCLC and may be a novel therapeutic target for NSCLC intervention.

[1]  D. Louis,et al.  Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A , 2000, Leukemia.

[2]  G. Watkins,et al.  The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. , 2008, International journal of oncology.

[3]  Yi-long Wu,et al.  Clinical trials and biomarker research on lung cancer in China , 2012, Expert opinion on therapeutic targets.

[4]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[6]  Seiichi Mori,et al.  An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. , 2008, Cancer cell.

[7]  C. Cordon-Cardo,et al.  Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. , 1999, Journal of the National Cancer Institute.

[8]  C. Goparaju,et al.  Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression , 2006, Molecular Cancer.

[9]  I. Choi,et al.  MicroRNA 135a Suppresses Lymph Node Metastasis through Down-Regulation of ROCK1 in Early Gastric Cancer , 2014, PloS one.

[10]  R. Trojanec,et al.  Non-small cell lung cancer--genetic predictors. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[11]  Yi-long Wu,et al.  Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Henriette O'Geen,et al.  Suz12 binds to silenced regions of the genome in a cell-type-specific manner. , 2006, Genome research.

[13]  V. Gorgoulis,et al.  E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus , 2007, Journal of Clinical Pathology.

[14]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[15]  T. Schroeter,et al.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity , 2009, Cellular and Molecular Life Sciences.

[16]  Marc Tessier-Lavigne,et al.  Roundabout Controls Axon Crossing of the CNS Midline and Defines a Novel Subfamily of Evolutionarily Conserved Guidance Receptors , 1998, Cell.

[17]  K. Struhl,et al.  Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. , 2010, Molecular cell.

[18]  J. Martens,et al.  EZH2 and Histone 3 Trimethyl Lysine 27 Associated with Il4 and Il13 Gene Silencing in TH1 Cells* , 2005, Journal of Biological Chemistry.

[19]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  Q. Cai,et al.  SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK , 2012, Molecular Cancer Research.

[22]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[23]  A. Klein-Szanto,et al.  E2F-1: a proliferative marker of breast neoplasia. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  S. Narumiya,et al.  Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion , 2009, Cancer and Metastasis Reviews.

[25]  K. Helin,et al.  Polycomb Complex 2 Is Required for E-cadherin Repression by the Snail1 Transcription Factor , 2008, Molecular and Cellular Biology.

[26]  R. Ganju,et al.  Slit-2 Induces a Tumor-suppressive Effect by Regulating β-Catenin in Breast Cancer Cells* , 2008, Journal of Biological Chemistry.

[27]  Jing Wang,et al.  The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells , 2014, BMC Cancer.

[28]  Denis Wirtz,et al.  Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells , 2013, Proceedings of the National Academy of Sciences.

[29]  C. Elmets,et al.  Neuronal Repellent Slit2 Inhibits Dendritic Cell Migration and the Development of Immune Responses1 , 2003, The Journal of Immunology.

[30]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[31]  T. Jenuwein,et al.  Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. , 2007, Cancer cell.

[32]  S. Krishnan,et al.  Regulation of Axon Guidance by Slit and Netrin Signaling in the Drosophila Ventral Nerve Cord , 2007, Genetics.

[33]  Pierre Validire,et al.  Integrated molecular portrait of non-small cell lung cancers , 2013, BMC Medical Genomics.

[34]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[35]  J. Zeitlinger,et al.  Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.

[36]  Ratnesh K Singh,et al.  Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene , 2007, Human Genetics.

[37]  J. Kench,et al.  Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  K. Naka,et al.  Expression of the E2F family in human gastrointestinal carcinomas , 1999, International journal of cancer.

[39]  M. Piris,et al.  Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. , 2010, The American journal of pathology.

[40]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[41]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[42]  Masaki Ueno,et al.  E2F1 Overexpression Correlates with Thymidylate Synthase and Survivin Gene Expressions and Tumor Proliferation in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[43]  Joon-Oh Park,et al.  Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy , 2008, Clinical Cancer Research.

[44]  Sijin Liu,et al.  Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. , 2009, Cancer research.

[45]  Sijin Liu,et al.  ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc , 2014, Oncogene.

[46]  M. Olson,et al.  Activating ROCK1 somatic mutations in human cancer , 2010, Oncogene.

[47]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  F. Hamdy,et al.  EZH2 promotes proliferation and invasiveness of prostate cancer cells , 2007, The Prostate.

[49]  A. McCourty,et al.  Title Immunohistochemical expression of cyclin D 1 , E 2 F-1 and Ki-67 in benign and malignant thyroid neoplasms , 2002 .

[50]  Giorgio F. Gilestro,et al.  Regulation of commissural axon pathfinding by slit and its Robo receptors. , 2006, Annual review of cell and developmental biology.

[51]  Donald C. Chang,et al.  Hyaluronan stimulates transformation of androgen-independent prostate cancer. , 2006, Carcinogenesis.

[52]  A. Look,et al.  Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. , 1995, Genomics.